Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | (28466956) | ||||||||||||
Authors | Haran M, Mirkin V, Braester A, Harpaz N, Shevetz O, Shtreiter M, Greenberg S, Mordich O, Amram O, Binsky-Ehrenreich I, Marom A, Shachar I, Herishanu Y, Ruchlemer R, Berrebi A, Valinsky L, Shtalrid M, Shvidel L | ||||||||||||
Title | A phase I-II clinical trial of the anti-CD74 monoclonal antibody milatuzumab in frail patients with refractory chronic lymphocytic leukaemia: A patient based approach. | ||||||||||||
|
|||||||||||||
URL | |||||||||||||
Abstract Text |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Milatuzumab | Milatuzumab | 0 | 0 |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Milatuzumab | IMMU-115|hLL1 | CD74 Antibody 3 | Milatuzumab (IMMU-115) is a monocloncal antibody to CD74 that induces apoptosis and targets tumor cells with high CD74 expression, such as B-cells (PMID: 25754579, PMID: 28466956). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|